Do you give EPOGEN before or after dialysis?
If prescribed by your doctor, your EPOGEN® treatment will probably be on the same schedule as your dialysis. EPOGEN® needs to be injected either into your skin or directly into your dialysis line. If you are on hemodialysis, it is recommended that you get EPOGEN® through your dialysis line.
When is EPOGEN contraindicated?
Epoetin alfa is contraindicated in patients with serious allergic reactions, such as anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria, to the product. Immediately and permanently discontinue epoetin alfa and administer appropriate therapy if a hypersensitivity reaction occurs.
Does EPOGEN affect your kidneys?
Epoetin alfa may sometimes cause or worsen high blood pressure, especially in patients with long-term kidney failure. This effect may be caused by the number of red blood cells increasing too quickly, usually within the first 3 months of starting treatment.
Why is EPOGEN given to dialysis patients?
Epoetin is used to treat severe anemia in patients on kidney dialysis or for those not on dialysis. Epoetin may also be used to prevent or treat anemia that is caused by surgery or medicines (eg, zidovudine) that are used for other conditions, such as HIV or cancer.
When should Epogen be administered?
Initiate Epogen treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Epogen.
How do you administer Epogen injections?
Epogen can be injected directly into a layer of fat under your skin. This is called a subcutaneous injection. When giving subcutaneous injections, follow your healthcare provider’s instructions about changing the site for each injection. You may wish to write down the site where you have injected.
How is Epogen injection administered?
Which client would epoetin alfa not be indicated?
Epoetin alfa is not indicated for patients with cancers that originate in the bone marrow, such as acute myelogenous leukemia. Epoetin alfa is not appropriate for the treatment of anemia from other causes such as iron or folate deficiency or gastrointestinal bleeding.
How do you administer epoetin?
Epoetin alfa injection products come as a solution (liquid) to inject subcutaneously (just under the skin) or intravenously (into a vein). It is usually injected one to three times weekly.
When should Epogen be used in a patient with renal failure?
For Adult Patients With CKD On Dialysis Initiate Epogen treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Epogen.
What should you check before administering epoetin alfa?
Monitoring and Testing While Taking Epoetin Alfa You will be monitored regularly by your doctor while you are taking epoetin alfa. Tests will include blood tests (specifically hemoglobin and hematocrit) and blood pressure measurements.
When is Epogen given?
Is Epogen safe for patients with chronic kidney disease?
Patients With Chronic Kidney Disease. The safety and efficacy of Epogen were evaluated in 13 clinical studies involving intravenous administration to a total of 1010 patients on dialysis with anemia. Overall, more than 90% of the patients treated with Epogen experienced improvement in hemoglobin concentrations.
What are the indications and limitations of Epogen?
Indication and Limitiations of Use. EPOGEN ® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis to reduce or avoid the need for red blood cell transfusions. EPOGEN ® has not been proven to improve quality of life, fatigue, or well-being.
Epogen can be injected in your vein through a special access port put in by your healthcare provider. This type of Epogen injection is called an intravenous (IV) injection. This route is usually for hemodialysis patients.
Is it safe to take Epogen for anemia?
IMPORTANT SAFETY INFORMATION ABOUT EPOGEN®. Indication. EPOGEN® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis to reduce or avoid the need for red blood cell transfusions.